drug · antibody
daratumumab + Gene Therapy
Phase 2updated 5mo agoby Indapta Therapeutics Inc🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 8- drugdaratumumab63 co-mentions · 18 sources
- tagApproval60 co-mentions · 15 sources
- drugDARZALEX FASPRO60 co-mentions · 15 sources
- drug(daratumumab + hyaluronidase (human recombinant))31 co-mentions · 16 sources
- companyJanssen Biotech Inc30 co-mentions · 15 sources
- tagOncology3 co-mentions · 2 sources
- tagImmunology2 co-mentions · 1 sources
- tagHematology2 co-mentions · 1 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and neoplasm and 37 investigational indications.
targets
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
all catalysts(0)
nothing on the calendar yet
Trials studying daratumumab + Gene Therapy
- phase3A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- phase22015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- phase2Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
- phase3A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- phase2A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- phase3Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- phase2A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- phase2Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
News(10)
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from CelgeneThe clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.biopharma_dive · 1mo ago
- STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classThe FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of drugs for the blood cancer.stat · 1mo ago
- BMS welcomes new multiple myeloma drug as generics batter current portfolioThe FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in…biospace · 1mo ago
- Legend Biotech CEO abruptly steps down without permanent replacementIn a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.fiercebiotech · 2mo ago
- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsJ&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.biopharma_dive · 2mo ago
- Medicare drug price rule may target under-the-skin Keytruda and OpdivoFor 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.biopharma_dive · 3mo ago
- J&J multiple myeloma drug gains edge in earlier stage diseaseThe latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.biopharma_dive · 3mo ago
- J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1BThe buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.biopharma_dive · 3mo ago
- 2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipelinebiopharma_dive · 4mo ago
- FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotechThrough two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…biopharma_dive · 5mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that